Plasma lipids and blood fluidity in patients with polygenic hypercholesterolaemia treated with fluvastatin

Clinical Hemorheology and Microcirculation

Volumn 27, Issue 3-4, 2002, Pages 193-199

  Piñon, Francisco ^a   Merino, J F ^a   Ferrer, J C ^a   Martinez M ^a   Vaya A ^a   Aznar, J ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

Fluvastatin; Haemorheology; Polygenic hypercholesterolaemia

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; FIBRINOGEN; FLUINDOSTATIN;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; BLOOD FILTER; BLOOD RHEOLOGY; BLOOD VISCOSITY; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHROCYTE; ERYTHROCYTE AGGREGATION; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MALE; PARAMETER; SHEAR STRESS;

ADULT; CASE-CONTROL STUDIES; CELL AGGREGATION; ERYTHROCYTES; FATTY ACIDS, MONOUNSATURATED; FEMALE; FIBRINOGEN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INDOLES; LIPID METABOLISM; LIPIDS; MALE; MIDDLE AGED; TIME FACTORS;

EID: 0346144496     PISSN: 13860291     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. W. Koenig, E. Ernst and A. Matrai, Blood rheology associated with cardiovascular risk factors and chronic cardiovascular diseases: Results of an epidemiological cross-sectional study, Angiology 38 (1988), 986-995.
2. A. Vayá, M. Martínez, J. Dalmau, M.M. Velert and J. Aznar, Hemorheological changes in children with familial hypercholesterolemia, Clin. Hemorheol. 16 (1996), 549-557.
3. A. Vayá, M. Martínez, J. Aznar, A. Gilsanz and J.L. Barberá, Hemorheological profile in primary hyperlipemic patients with and without ischemic events, Rev. Iberomer. Thromb. Hemostasia 8 (1995) 74-77.
4. A. Vayá, M. Martínez, V. Morenoand and J. Aznar, Erythrocyte deformability in patients with primary hypertriglyceridemia, Clin. Hemorheol. 14 (1994) 419-420.
5. W. Marz and H. Wieland, HMG-CoA reductase inhibition: anti-inflammatory effects beyond lipid lowering? Herz 25(25) (2000), 117-125.
6. B. Kwak, F. Mulhaupt, S. Myit and F. Mach, Statins as a newly recognized type of immunomodulator, Nat. Med. 12(6) (2000), 1399-1402.
7. C.P. Sparrow, C.A. Burton, M. Hernández et al., Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering, Arterioscler. Thromb. Vasc. Biol. 21(1) (2001), 115-121.
8. J.H. Griffin, J.A. Fernández and H. Deguchi, Plasma lipoproteins, hemostasis and thrombosis, Thromb. Haemost. 86(1) (2001), 386-394.
9. J.C. LaRosa, Pleiotropic effects of statins and their clinical significance, Am. J. Cardiol. 88(3) (2001), 291-293.
10. W. Koenig, R. Hehr, H.H. Ditschuneit and J.P. Staub, The effects of Lovastatin on blood rheology, in: 7th European Conference on Clin. Hemorheol., Southampton, UK, 1991, p. 110 (abstract).
11. M. Martínez, A. Vayá, R. Martí, L. Gil, I. Lluch, R. Carmena and J. Aznar, Erythrocyte membrane cholesterol/phospholipid changes and hemorheological modificacions in familial hypercholesterolemia treated with lovastatin, Throm. Res. 83 (1996), 375-388.
12. Y. Beigel, J. Fuchs, M. Snir, Y. Lurie, P. Green and M. Djaldetti, Lovastatin therapy in heterozygous familial hypercholesterolemic patients: effect on blood rheology and fibrinogen levels, J. Intern. Med. 230(1) (1991), 23-27.
13. Y. Levy, R. Leibowith, M. Aviram, J.G. Brook and U. Cogan, Reduction of plasma cholesterol by lovastatin normalyzes erythrocyte membrane fluidity in patients with severe hypercholesterolaemia, Br. J. Clin. Pharmacol. 34 (1992), 427-430.
14. A. Vayá, M. Martínez, R. Carmena and J. Aznar, Red blood cell aggregation and primary hyperlipoproteinemia, Thromb. Res. 72 (1993), 119-126.
15. R.H. Jay, M.W. Rampling and D.J. Betteridge, Abnormalities of blood rheology in familial hypercholesterolemia: effect of treatment, Atherosclerosis 85 (1990), 249-256.
16. H.R. Arntz, G. Zingler, S.V. Oldenburg, M.L. Heineking, W. Marz, R. Siekmeier and R. Schroder, Influence of pravastatin on blood rheology in type II hypercholesterolemia, in: 7th European Conference on Clin. Hemorheol., Southampton, UK, 1991, p. 110 (abstract).
17. P.H. Jones, A clinical overview of dyslipemias: treatment strategies, Am. J. Med. 93 (1992), 187-198.
18. International Committee for Standarization in Haematology, Expert Panel on Blood Rheology, Guidelines for measurement of blood viscosity an erythrocyte deformability, Clin. Hemorheol. 6 (1986), 439-453.
19. G.R. Warnick and J.J Abers, A comprehensive evaluation of the heparin-manganese precipitation procedure for estimating hig density lipoprotein cholesterol, J. Lip. Res. 19 (1978), 65-76.
20. C.C. Heuck and C. Schlierf, Nephelometry of apolipoprotein B in human serum, Clin. Chem. 25 (1979), 221-226.
21. F. Jung, H.G. Roggenkamp, R. Schneider and H. Kiesewetter, Das Kapillarschlauch-Plasmaviskosimeter ein neues Mess-geraet zur Quantifizierung der Blutplasmaviskositaet, Biomed. Technik 28 (1983), 249-252.
22. H. Schmid-Schonbein, E. Volger, P. Teitel, H. Kiesewetter and V. Daver and L. Heilmann, New hemorheological techniques for the routine laboratory, Clin. Hemorheol. 2 (1982), 93-105.
23. P. Ruef, J.M.B. Poschl, O. Linderkamp and H. Schmid-Schönbein, The shear stress diffractometer Rheodyn SSD for determination of erythrocyte deformability: sensivity to detect abnormal deformability, Clin. Hemorheol. 16 (1996), 749-752.
24. R.H. Knopp, Drug treatment of lipid disorders, N. Engl. J. Med. 341(7) (1999), 498-511.
25. G.L. Plosker and J. Wagstaff, Fluvastatin. A review of its pharmacology and use in the management of hypercholesterolaemia, Drugs 51(3) (1996), 433-459.
26. S. Muller, O. Ziegler, M. Donner, P. Drouin and J.F. Stolz, Rheologic properties and membrane fluidity of red blood cell and platelets in primary hyperlipoproteinemia, Atherosclerosis 83 (1990), 231-237.
27. S.M. Razavian, V. Atger, P. Giral et al., Influence of HDL subfraccions on erythrocyte aggregation in hypercholesterolemic men. PCV METRA group, Arterioscler. Thromb. 14 (1994), 351-366.
28. G. Caimi, R. Lo Presti, B. Canino et al., Hemorheologic profile of hyperlipemic patients with gemfibrozil, Curr. Therap. Res. 57 (1996), 327-335.
29. M. Labios, M. Martínez, A. Vayá, F. Gabriel, V. Guiral and J. Aznar, Effect of a modified fibrate (biniwas Retad) on hemorheological alteracions in hyperlipemic patients, Clin. Hemorheol. Microcirc. 21 (1999), 79-85.
30. F. Jung, C. Pindur and H. Kieseweter, Plasma viscosity dependence on proteins and lipoproteins: Results of the Aachen-study, Clin. Hemorheol. 12 (1992), 557-571.
31. R.I. Illigworth, S. Bacon, A.S. Pappu and G.J. Sexton, Comparative hypolipidemic effects of lovastatin and simvastatin in patients with heterozygous familial hypercholesterolemia, Atherosclerosis 96 (1992), 53-64.
32. A. Branchi, A. Rovellini, D. Sommariva, A.G. Gugliandolo and A. Fasoli, Effect of three fibrate derivatives and of two HMG_CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia, Thromb. Haemost. 70 (1993), 241-243.
33. M. Martínez, A. Vayá, M.L. Micó, J.L. Barberá and J. Aznar, Efecto de la simvastatina sobre las características hemorreológicas de pacientes con hipercolesterolemia primaria, Rev. Iberoamer. Tromb. Hemostasia 8 (1995), 20-23.
34. Y. Tsuda, K. Satoh, M. Kitadai, T. Takahashi, Y. Izumi and N. Hosomi, Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia, Atherosclerosis 122 (1996), 225-233.
35. D.R. Nair, J.A. Papadakis, I.A. Jagroop, D.P. Mikhailidis and A.F. Winder, Statins and fibrinogen, Lancet 351 (1998), 1430-1432.
36. H. Sinzinger, M. Rodrigues and C.D. Furberg, Dosing of atorvastatin and increases in fibrinogen level, Atherosclerosis 147 (1999), 421-422.